Transcode Therapeutics Correlations
| RNAZ Stock | USD 8.91 1.06 10.63% |
The current 90-days correlation between Transcode Therapeutics and In8bio Inc is 0.08 (i.e., Significant diversification). The correlation of Transcode Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Transcode Therapeutics Correlation With Market
Good diversification
The correlation between Transcode Therapeutics and DJI is -0.05 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Transcode Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Transcode | Build AI portfolio with Transcode Stock |
Moving together with Transcode Stock
Moving against Transcode Stock
| 0.31 | KURA | Kura Oncology | PairCorr |
| 0.37 | CAPR | Capricor Therapeutics | PairCorr |
| 0.37 | FCAP | First Capital Downward Rally | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Transcode Stock performing well and Transcode Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Transcode Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INAB | 5.05 | 0.19 | 0.02 | (3.03) | 5.06 | 14.29 | 37.96 | |||
| LYRA | 5.57 | (1.38) | 0.00 | (1.19) | 0.00 | 13.48 | 66.89 | |||
| APVO | 4.76 | (1.94) | 0.00 | (1.27) | 0.00 | 7.81 | 43.37 | |||
| GLTO | 11.20 | 3.74 | 0.48 | 0.62 | 6.96 | 17.97 | 273.14 | |||
| PHIO | 3.23 | (1.15) | 0.00 | (0.44) | 0.00 | 5.22 | 19.15 | |||
| HCWB | 5.07 | (1.76) | 0.00 | (0.85) | 0.00 | 13.02 | 41.72 | |||
| KPRX | 2.56 | (0.11) | 0.00 | (0.33) | 0.00 | 5.32 | 16.69 | |||
| APRE | 3.88 | (1.07) | 0.00 | (1.98) | 0.00 | 4.40 | 46.26 | |||
| BOLT | 3.26 | 0.08 | 0.01 | 0.20 | 3.97 | 8.22 | 18.19 | |||
| ACXP | 4.54 | (1.20) | 0.00 | (0.55) | 0.00 | 10.84 | 49.19 |
Transcode Therapeutics Corporate Management
| RN MBA | Senior Operations | Profile | |
| Daniel MD | Chief Officer | Profile | |
| Anna Moore | Scientific CoFounder | Profile | |
| Calais Pharm | Executive Board | Profile | |
| Robert Dudley | CEO, CoFounder | Profile |